Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy
European Journal of Cancer · 2024-03 · 199 · 113563
DOI: 10.1016/j.ejca.2024.113563 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2024-03. Verfasst von Sarah K Jacques und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Westmead and Blacktown Hospitals, Sydney, Australia. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Melanoma Institute Australia, National Health and Medical Research Council, University of Sydney.
Abstract (Originalsprache)
IMPORTANCE: Acral (AM) and mucosal melanomas (MM) are rare subtypes with a poor prognosis. In those with advanced disease, anti-PD-1 (PD1) therapy has reduced activity compared to that seen in non-acral cutaneous melanoma. OBJECTIVE: To determine the efficacy of adjuvant PD1 in resected AM or MM. DESIGN: An international, retrospective cohort study SETTING: Data up to November 2021 collected from 20 centres across 10 countries. PARTICIPANTS: One hundred and ninety four patients with resected stage III or IV1 AM or MM who received adjuvant PD1 were included and compared to matched patients from the Melanoma Institute Australia (MIA) database using a propensity score matching analysis. MAIN OUTCOMES AND MEASURES: Recurrence-free survival (RFS), distant metastasis-free survival (DMFS) and overall survival (OS) were investigated. RESULTS: Forty five of 139 (32%) AM and 9 of 55 (16%) MM patients completed adjuvant therapy. The main reason for early treatment cessation in both groups was disease recurrence: 51 (37%) and 30 (55%) in the AM and MM groups, respectively. In the AM group adjuvant PD1 was associated with a longer RFS [HR-0.69 (0.52-0.92, p = 0.0127)], DMFS [HR0.58 (0.38-0.89, p = 0.0134)] and OS [HR of 0.59 (0.38-0.92, p-value 0.0196)] when compared to the historical cohort. In the MM group there was no statistical difference in RFS [HR1.36 (0.69-2.68,p-value 0.3799], DMFS or OS. CONCLUSION AND RELEVANCE: After adjuvant PD1, both AM and MM have a high risk of recurrence. Our data suggests a benefit to using adjuvant PD1 therapy in resected AM but not in resected MM. Additional studies to investigate the efficacy of adjuvant PD1 for MM are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Westmead and Blacktown Hospitals, Sydney, Australia.
- Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
- Vanderbilt University Medical Centre, Nashville, TN, USA.
- Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany.
- Department of Dermatology, University Hospital of Zurich and Faculty of Medicine, University of Zürich, Zurich, Switzerland.
- MD Anderson Cancer Center, Houston, TX, USA.
Förderung
- Melanoma Institute Australia
- National Health and Medical Research Council
- University of Sydney
Zitieren
APA
Jacques, S. K., McKeown, J., Grover, P., Johnson, D. B., Zaremba, A., Dimitriou, F., Weiser, R., Farid, M., Namikawa, K., Sullivan, R. J., Rutkowski, P., Lebbe, C., Hamid, O., Zager, J. S., Michielin, O., Neyns, B., Nakamura, Y., Robert, C., Mehnert, J., …, & Carlino, M. S. (2024). Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy. European Journal of Cancer, 199, 113563. https://doi.org/10.1016/j.ejca.2024.113563
Vancouver
Jacques SK, McKeown J, Grover P, Johnson DB, Zaremba A, Dimitriou F, et al. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy. European Journal of Cancer. 2024;199:113563. doi:10.1016/j.ejca.2024.113563
BibTeX
@article{Jacques2024,
author = {Jacques, Sarah K and McKeown, Janet and Grover, Piyush and Johnson, Douglas B and Zaremba, Anne and Dimitriou, Florentia and Weiser, Roi and Farid, Mohamad and Namikawa, Kenjiro and Sullivan, Ryan J and Rutkowski, Piotr and Lebbe, Celeste and Hamid, Omid and Zager, Jonathan S and Michielin, Olivier and Neyns, Bart and Nakamura, Yasuhiro and Robert, Caroline and Mehnert, Janice and Ascierto, Paolo A and Bhave, Prachi and Park, Benjamin and Zimmer, Lisa and Mangana, Joanna and Mooradian, Megan and Placzke, Joanna and Allayous, Clare and Glitza Oliva, Isabella C and Mehmi, Inderjit and Depalo, Danielle and Wicky, Alexandre and Schwarze, Julia K and Roy, Severine and Boatwright, Christina and Vanella, Vito and Long, Georgina V and Menzies, Alexander M and Lo, Serigne N and Carlino, Matteo S},
title = {Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy},
journal = {European Journal of Cancer},
year = {2024},
volume = {199},
pages = {113563},
doi = {10.1016/j.ejca.2024.113563}
}
EUVIMED